Effectiveness of Co-Testing in Cervical Cancer Screening Program in Macao SAR

Background: Cervical cancer remains a significant public health concern in Macao SAR despite the implementation of a cervical cancer screening program and HPV vaccination. To improve early detection, Macao SAR introduced HPV DNA testing alongside cytology (co-testing) as the primary screening method in 2019. This study evaluates the effectiveness of co-testing in identifying cervical precancerous lesions (CIN2+) compared to cytology alone. Methods: We conducted a retrospective analysis of women aged 30 - 65 years who participated in the routine cervical cancer screening program in Macao SAR Primary Healthcare Centers from 2019 to 2022. Data from over 70,000 women were analyzed, comparing the detection rates of CIN2+ through co-testing and cytology alone. Women with abnormal cytology or positive HPV results were referred for colposcopy. Results: The introduction of co-testing led to a significant increase in the detection of CIN2+, particularly in women with atypical squamous cells of undetermined significance (ASCUS) or negative for intraepithelial lesion or malignancy (NILM) cytology results. Between 2019 and 2022, the percentage of women with ASCUS/NILM and any high-risk HPV (hrHPV) positive who were diagnosed with CIN2+ after colposcopy were 24%, 13%, 10% and 7.5% respectively. This highlights the ability of co-testing to identify high-risk individuals who would have been missed by cytology alone. Discussion: Our findings demonstrate the effectiveness of co-testing in improving the sensitivity of cervical cancer screening in Macao SAR. The inclusion of HPV DNA testing allows for better risk stratification of women with ASCUS/NILM cytology, leading to more targeted referrals for colposcopy and timely detection of precancerous lesions. The initial high positive rate in 2019 (24%) might be attributed to the small sample size and potentially reflects a backlog of undiagnosed cases prior to co-testing implementation. Conclusion: The implementation of co-testing in Macao SAR’s cervical cancer screening program significantly improves the early detection of precancerous lesions, particularly in women with ambiguous cytology results. This proactive approach contributes to reducing cervical cancer morbidity and mortality and improving women’s health outcomes in Macao SAR.

Perceived Barriers to Cervical Cancer Screening Using Pap Smear Test among Women Attending Saad Abu Al Ella Hospital in Khartoum State, 2022

Background: Cervical cancer is the second common cancer among women worldwide. It is a preventable cancer, and early detection of precancerous conditions through the Papanicolaou cytology screening (Pap smear) is a key aspect of prevention;it is accepted worldwide as an efficient tool for secondary prevention. While the PS test is simple, inexpensive, and relatively reliable as a method of diagnosing cervical cancer, most women do not take the test. Therefore, this study is sought to describe the barriers to pap smear uptake among Sudanese women. Materials and Method: This total coverage observational, analytical and cross sectional, hospital-based study was conducted in Saad Abu El Ella Hospital in April 2022. The study was conducted using an anonymous questionnaire to assess the perceived barriers of 93 participants. All data were computerized using Microsoft Excel’17 and the data were described and analyzed using statistical package for social science (SPSS23). Results: The findings revealed that the mean age of the participants was 39.5 years and only 3.2% had ever undergone a pap smear test. Identified barriers were lack of information, not knowing where to go, and fear of pain. The majority, 72% are willing to routinely perform a pap smear test if well informed about it. The study also demonstrates that there is a significant correlation between perceived barriers score and willingness to perform the pap smear test (p value = 0.008), and between the perceived barriers score and the sociodemographic factors: Age (p value = 0.006), educational level (p value = 0.028) and occupation (p value = 0.040), but no association with the economic status was found (p value = 0.378). Conclusion: The detection rate is too low compared to the national target of over 70%. Therefore, more work is needed to reduce perceived barriers to cervical cancer screening by providing education/raising for popular awareness;addressing misconceptions and false beliefs;informing women about the necessity and importance of Pap smear;and health promotion using mass media such as national television, social media, radio, billboards, and newspapers and other print media.

Cervical Cancer Prevention Challenges and Barriers to Cervical Cancer Screening and HPV Vaccinations in Ukraine and Eastern Europe

Objectives: To identify the obstacles and issues that hinder effective cancer prevention efforts in Ukraine. The study aims to provide a comprehensive assessment of the barriers to cancer prevention, including both infrastructure and behavioral factors, and identify potential solutions to address these challenges. Study Design: Comprehensive literature review. Methods: The following databases were searched: National Center for Biotechnology Information (NCBI) and PubMed (U.S. National Library of Medicine at the National Institutes of Health). The keywords used in the search included “Cervical Cancer”, “Human Papillomavirus Vaccination (HPV)”, “Ukraine”, “Eastern Europe”, “Healthcare Infrastructure in Disasters”, “Cervical Cancer Prevention”, “Pap Smear”, and “HPV Testing”. Results: A total of 3500 articles were screened. A total of 65 articles met the inclusion criteria. Limited public awareness and limited access to vaccination and screening, combined with inadequate treatment facilities lead to higher rates of cervical cancer. The COVID pandemic, war with Russia, and the Chernobyl disaster are significant factors for the low level of vaccination in Ukraine. Conclusion: The prevention and treatment of cervical cancer in Ukraine face significant challenges due to the inadequate HPV vaccination rates and screening by cytology. Efforts to improve funding and increase education of both the population and health care providers are necessary to increase interventions such as HPV vaccination, cervical cytology, and HPV testing to reduce cervical cancer rates in Ukraine.

Factors associated with cervical cancer knowledge and practice among Bahraini women

The study was conducted to assess the women’s knowledge and attitude towards cervical cancer and cervical cancer screening,to support the health education programs in this field.A total sample of 350 women(n = 350 ),70 women from each health center was chosen based on a multistage sampling technique according to a number of 21 health centers that serve the population.One health center from each government was selected based on the population it serves,thus the health center with the highest population number was chosen.The main tool of data collection was a face to face interview questionnaire.When assessing the knowledge,attitude, and practice(KAP) of our sample,we observed that approximately equal percentages(70%) of women have heard of both Pap smear and cervical cancer.Only 47.4%had ever had Pap smear and of those 35.1% had it during a period of 5 years or less.The main source of knowledge for those who have done the procedure is the family physician(30.8%).When asked about the reason behind having a Pap smear,the majority (62.3%) had it during postnatal visits.Nevertheless,those that didnt have it,almost half(46.6%) disapproved to do so because they are healthy even after being told that Pap smear is a painless significant procedure. In conclusion,majority of respondents have a good knowledge about cervical cancer but is not reflected in their practice.The results strongly recommend continued health education for the women which can be achieved through the introduction of this topic into the schools’curriculum and planning educational programs within antenatal and postnatal visits.

Cytological Changes of Oral Cavity and of High/Low Risk HPV Detection in Women with Cervical Pathology

Oropharyngeal tumor is the eight most common cause of cancer death worldwide. Among the causes of oropharyngeal carcinoma significant are cigarette smoking, abuse of alcohol, multi-partners, high risk HPV (Human Papillomavirus) and etc. Cytological material (oral Pap smear) was taken from oral fundus and cheek mucous by the cytobrush. 47 participants with cervix pathology and 42 participants of the control group were investigated. Oral smears were stained by the Papanicolaou method and were diagnosed by a double blind method. After the cytological examination, we carried out detecting low and high risk HPV by chromogenic in-situ hy-bridization (CISH method) to use a positive and negative control. The quantitative statistical analysis was performed by SPSS V.19.0. Numeral data were processed using Pearson correlation and X2 tests. Confidence interval of 95% was regarded statistically significant. Study group’s oral pap smear with atypical cytology was detected in 61.7%. Atypical cytological changes in the control group were confirmed in 38.0%. High risk HPV detection by the CISH, in study group, showed positivity in 46.8% and in the control group—in 4.8%. Participants with cervix pathology will be considered as a risk-group to develop oropharyngeal tumor. Screening program for oropharyngeal cancer combines Pap smear and high risk HPV test together. For the control group, it is recommended to use oral pap smear and in the case of atypical changes using high risk HPV test too.

HPV检测、TCT及宫颈刮片在宫颈癌和癌前病变筛查中的应用

目的:评价HPV检测、TCT(膜式液基薄层细胞学检查)及宫颈刮片在宫颈癌和癌前病变筛查中的应用价值。方法:对我院妇科门诊1008例发现宫颈异常(宫颈糜烂、肥大、接触性出血、溃疡及乳头样增生等)的患者进行HPV检测、TCT及宫颈刮片,对1项或多项异常者行病理组织学检查,并以病理结果为标准。对病理结果阳性的182例患者,比较3种方法的检出敏感度、高度病变和浸润癌的阳性符合率。结果:HPV检测、TCT和宫颈刮片结果阳性分别为158例、149例和98例,敏感度分别为86.8%、81.8%和53.8%,高度病变和浸润癌的阳性符合率分别为91.4%、85.0%和60.0%。宫颈刮片与TCT、HPV检测的敏感度及高度病变和浸润癌的阳性符合率都有明显差异(P<0.01),而TCT和HPV检测没有明显差异(P>0.05)。结论:TCT和HPV检测能够提高检出敏感度和高度病变的阳性符合率,在宫颈癌和癌前病变筛查中,我们可以用TCT或HPV检测提高检出率。

HPV分型检测在宫颈细胞学阴性妇女宫颈病变诊断中的临床意义

目的探讨30岁及以上、宫颈细胞学检查未见异常的妇女行人乳头瘤病毒(HPV)分型检测在宫颈病变诊断中的临床价值。方法收集126例薄层液基细胞学(TCT)未见异常但HPV16、18、31、33、45阳性的30岁及以上妇女的资料,以阴道镜活检组织病理结果为诊断标准,分析HPV分型与宫颈组织病理结果的关系。结果 126例受检妇女中,检出CINⅠ级10例(7.9%),CINⅡ/Ⅲ级18例(14.3%);其中75例HPV16阳性妇女中检出CINⅡ/Ⅲ级15例(20%),15例HPV18阳性妇女中检出CINⅡ/Ⅲ级1例(6.7%),16例HPV31阳性、27例HPV33阳性者中分别检出CINⅡ/Ⅲ级1例(6.3%)、2例(7.4%)。按各型别是否检出CINⅡ/Ⅲ级进行单因素Logistic回归分析,发现感染HPV16者发生CINⅡ/Ⅲ级病变的风险是未感染HPV16者的4倍(95%CI 1.094-14.624,P=0.026<0.05)。结论宫颈细胞学无异常但HPV16、18、31、33、45阳性的30岁及以上妇女存在一定的发生宫颈高级别病变的风险,尤其是HPV16感染者,建议及时行阴道镜检查。

宫颈刮片、阴道镜及HPV检测在诊断宫颈癌和癌前病变中的应用

目的:评价宫颈刮片、阴道镜及高危HPV检测在宫颈癌及癌前病变诊断中的效果。方法:对发现宫颈异常的患者同时进行宫颈刮片、阴道镜检查及高危HPV检测,对一项或多项异常者行病理组织学检查,并以病理结果为金标准。对134例病理结果阳性(CIN Ⅰ、CINⅡ、CINⅢ、宫颈浸润癌)的患者,比较三种方法的检出敏感度。结果:宫颈刮片阳性者70例,敏感度为52.2%,阴道镜108例,敏感度为80.6%,两者阳性检出率相比有极显著差异(P<0.01)。高危HPV感染者阳性118例, 敏感度88.1%,与宫颈刮片的敏感度相比有极显著差异(P<0.01),与阴道镜的敏感度相比,有显著差异(P<0.05)结论:对于宫颈癌及其癌前病变的筛查及早期诊断,应以宫颈细胞学检查和阴道镜检查及高危HPV检测相互结合以提高检出率,降低假阴性。

宫颈刮片、阴道镜及HPV检测在宫颈癌筛查中的应用

目的评价宫颈刮片、阴道镜及高危HPV检测在宫颈癌筛查中的作用。方法对发现宫颈异常的患者同时进行宫颈刮片、阴道镜检查及高危HPV检测,对一项或多项异常者行病理组织学检查,并以病理结果为金标准。对167例病检结果阳性(C INⅠ、C INⅡ、C INⅢ、宫颈浸润癌)的患者,比较三种方法的检出敏感性、特异性、阳性预测值和阴性预测值。结果宫颈刮片检测的敏感性为37.72%,特异性为89.01%,阳性预测值为54.07%,阴性预测值为83.74%;阴道镜检敏感性为61.08%,特异性为70.51%,阳性预测值为33.75%,阴性预测值为81.91%;高危HPV感染阳性126例,敏感性75.45%,特异性为57.51%,阳性预测值为35.2%,阴性预测值为88.45%。三种方法的敏感性比较差异有统计学意义(P<0.05)。结论对于宫颈癌及其癌前病变的筛查及早期诊断,应以宫颈细胞学检查和阴道镜检查及高危HPV检测相互结合以提高检出率,降低假阴性。

高危型HPV联合TCT在宫颈癌筛查中的价值研究

目的:探讨高危型人乳头瘤病毒(HPV)联合液基薄层细胞检测技术(TCT)在宫颈癌筛查中的价值。方法:选择2014年6月至2016年12月在我院就诊接受HR-HPV及TCT检测的1426例患者,并行阴道镜活检做病理组织学诊断,对TCT、HR-HPV以及TCT联合HR-HPV检测结果分析。结果:从CINⅠ级、CINⅡ级、CINⅢ级至SCC患者TCT检测阳性率呈显著升高趋势,与宫颈炎组比较差异均具有统计学意义(P<0.05)。在多重感染患者中,其CINⅠ级、CINⅡ级、CINⅢ级至SCC患者HPV感染率显著高于宫颈炎组,比较差异均具有统计学意义(P<0.05),患者随着CIN分级的增加HR-HPV检测阳性率而显著升高,与宫颈炎组比较差异均具有统计学意义(P<0.05)。在TCT联合HPV检测中,CINⅠ~CINⅢ级及SCC组HPV感染均非常显著高于宫颈炎组,比较差异均具有统计学意义(P<0.05)。TCT联合HR-HPV检测在灵敏度、特异度、阳性预测值、阴性预测值均显著优于TCT、HR-HPV单独检测,比较差异均具有统计学意义(P<0.05)。结论:高危型HPV联合TCT在宫颈癌筛查中较单一检测可明显减少漏诊率、误诊率,使宫颈癌前病变患者早期介入治疗,降低宫颈癌患者发病率及病死率。

液基薄层细胞学检查、HPV-DNA检测、阴道镜检查在宫颈癌早期诊断中的临床应用价值分析

目的分析及探讨宮颈癌早期诊断中应用液基薄层细胞学(TCT)检查、阴道镜检查及HPV-DNA检测的价值。方法收集本科室2012年1月~2013年12月间接收的经TCT检查未明确诊断意义的200例宫颈非典型鳞状细胞病变患者,均安排行阴道镜检查、HPV-DNA检测,总结分析患者的检测结果情况。结果阴道镜与HPV-DNA检测的灵敏度较TCT检查的灵敏度高,HPV-DNA检查的灵敏度最高(P<0.05);随着患者TCT检查病变级别的上升,患者的HPV检查阳性率也随之上升,其中ASCUS与LSIL患者的HPV检查阳性率差异有统计学意义(P<0.05)。LSIL与HSIL组患者的病理活检阳性率较ASCUS组患者显著更高,其中又以HSIL组的阳性率最高(P<0.05)。结论针对TCT检查有异者加用阴道镜检查与HPV-DNA检测联合筛查,能够有效提高宫颈癌的早期诊断率,值得临床借鉴推广。

人乳头瘤病毒、液基薄层细胞学检查、阴道镜联合检查在早期宫颈病变诊断中的应用价值

目的:分析人乳头瘤病毒(HPV)、液基薄层细胞学检查(TCT)、阴道镜联合检查在早期宫颈病变诊断中的应用价值。方法:选取2020年1月—2022年12月滨州医学院附属医院收治的400例疑似早期宫颈病变患者作为研究对象,均进行HPV、TCT、阴道镜检查及病理检查,以病理检查结果为“金标准”,比较HPV联合TCT检查与HPV、TCT联合阴道镜检查对早期宫颈病变的诊断效能。结果:400例疑似早期宫颈病变患者中,病理诊断检测出阳性350例,阴性50例。HPV、TCT联合阴道镜检查诊断早期宫颈病变的灵敏度、符合率高于HPV联合TCT检查,特异度低于HPV联合TCT检查,差异有统计学意义(P<0.05)。结论:HPV、TCT、阴道镜联合检查诊断早期宫颈病的灵敏度及符合率较高,适用于早期宫颈癌病变的诊断。

宫颈刮片、阴道镜及HPV检测在宫颈癌筛查中的体会

目的:总结宫颈刮片、阴道镜及HPV检测在宫颈病变诊断中的临床经验,对宫颈癌筛查提出合理化建议。方法:对3种方法任何一项检测异常者行阴道镜下病理活检及宫颈管搔刮,以组织学诊断作为金标准。对212例病理结果阳性(CINI、CINII、CINIII、宫颈浸润癌)的患者,比较3种方法的检出敏感度,及在细胞学及阴道镜检查中漏诊的临床体会。结果:212例病理结果阳性者中,宫颈刮片阳性者151例,敏感度为71.23%,阴道镜阳性者167例,敏感度为78.77%,两者阳性检出率相比无显著性差异(P>0.05)。高危型HPV感染者182例,敏感度83.02%,与阴道镜的敏感度相比,无显著性差异(P>0.05),与宫颈刮片相比,有显著性差异(P<0.05)。结论:宫颈癌的筛查及早期诊断,应以宫颈细胞学检查、阴道镜检查及HPV检测相互结合以提高检出率。

宫颈脱落细胞学和HPV检测应用于宫颈癌诊断的价值分析

目的评价宫颈脱落细胞学、HPV检测对宫颈癌检测的准确性。方法选取40例拟诊宫颈癌受检者,分别进行宫颈脱落细胞学、HPV检测检测,对两种细胞学方法检测结果进行对比。然后以阴道镜下组织病理学结果作为金标准,比较两种细胞学方法对宫颈癌筛查的准确性进行诊断价值的评价。结果 40例拟诊宫颈癌中,组织病理学确诊阳性36例,阴性4例。宫颈脱落细胞学与HPV检测对于宫颈癌与组织病理学病变检出率比较无统计学意义(P>0.05)。按金标准分别对两种检查结果进行诊断试验评价,检出宫颈癌的灵敏度比较无显著差异(P>0.05),而特异度比较有显著差异(P<0.05)。结论宫颈脱落细胞学与HPV检测对宫颈癌的筛查有较高的检出率,敏感性都比较好,但是特异性都存在不足,在临床上建议共同采用,以提高宫颈癌诊断的准确率。

TCT、HPV和阴道镜在门诊宫颈癌筛查中的应用

目的探讨新柏氏液基细胞学检测(TCT)、人乳头状瘤病毒(HPV)和阴道镜在门诊宫颈癌筛查中的应用效果。方法选取2019年1—12月在该院接受宫颈癌筛查的2000例疑似患者,均以手术病理检查结果作为金标准,接受TCT、HPV以及阴道镜活检,分析比较单独使用TCT、HPV以及联合TCT、HPV与阴道镜3种方式宫颈癌检查准确情况。结果2000例疑似患者中共有1307例患者确认,其中524例为CINⅠ、449例为CINⅡ、332例为CINⅢ、2例为浸润癌,HPV筛选结果为CINⅠ508例(96.95%)、CINⅡ432例(96.21%)、CINⅢ315例(94.88%)、浸润癌1例(50.00%);TCT筛选结果为CINⅠ476例(90.84%)、CINⅡ405例(90.20%)、CINⅢ298例(89.76%)、浸润癌1例(50.00%);3种技术联合筛选结果为CINI524例(100.00%)、CINⅡ449例(100.00%)、CINⅢ332例(100.00%)、浸润癌2例(100.00%),3种技术联合筛选结果的诊断准确率高于单独检查,差异有统计学意义(P<0.05)。结论在门诊宫颈癌筛查中采用采用TCT、HPV联合阴道镜,可及早发现患者病情情况,方便医护人员及时采取有效措施治疗。

宫颈刮片、阴道镜及HPV检测在宫颈病变筛查的应用

目的评价宫颈刮片、阴道镜、高危HPV检测在宫颈癌及宫颈癌前病变诊断中的效果。方法对发现宫颈异常的患者进行宫颈刮片、阴道镜、HPV检测,对一项或多项异常者进行病理组织学检查,并以病理结果为金标准。对208例病理结果阳性(CINⅠ、CINⅡ、CINⅢ、宫颈浸润癌)的患者,比较3种方法的检出敏感度。结果宫颈刮片阳性者108例,敏感度为51.92%,阴道镜168例,敏感度为80.70%,两者阳性检出率相比有极显著差异(P<0.01)。高危HPV感染者阳性者183例,敏感度为87.98%,与宫颈刮片的敏感度相比有极显著差异(P<0.01)。与阴道镜的敏感度相比,有显著差异(P<0.05)。结论对于宫颈癌及宫颈癌前病变的筛查及早期诊断,应以宫颈细胞学检查和阴道镜检查及高危HPV检测相互结合以提高检出率。

阴道镜联合液基细胞学技术和Hpv检测在宫颈癌前病变诊断中的价值探讨

目的分析阴道镜联合液基细胞学技术和Hpv检测在宫颈癌前病变诊断中的价值。方法本次研究对象是宫颈癌前病变患者650例TCT和(或)HPV阳性,时间在2019年3月至2020年2月,将患者随机分成两组,参照组(n=325)均予以HR-HPV和TCT检测,实验组(n=325)在HR-HPV和TCT检测同时联合阴道镜定位活检术,对比二组患者的宫颈上皮内瘤变阳性率。结果实验组患者的宫颈上皮内瘤变阳性率为50.15%,高于参照组的31.38%,组间数据对比存在显著差异(P<0.05);对实验组确定为宫颈癌的患者进行手术治疗,其中3例宫颈癌术后Hpv持续阳性,术后随访中定期进行阴道镜定位下活检,最后均确诊为阴道癌。结论为HR-HPV和TCT检测结果为阳性者,行阴道镜定位活检具有一定优势,可有效提升宫颈癌前病变的诊断准确率,以便临床为患者采取及时、有效的治疗措施,利于预后。

Comparative Study of care HPV Assay,Visual Inspection and Pap Smears as Primary Screening in Rural China

农村地区的肿瘤早诊早治,一直是国家肿瘤防治工作的重点。本文旨在研究在我国农村地区,在当地现实条件下由基层技术人员操作的醋酸碘染色肉眼观察、细胞学以及careHPV DNA检测的可行性。本研究中把当地参加项目的女性随机分为3组,分别采用醋酸碘染色肉眼观察、细胞学以及careHPV DNA进行宫颈癌及癌前病变的初筛。初筛阳性的女性转诊进行阴道镜及活检。所有的检测都是有当地工作人员完成。最终诊断以中国医学科学院肿瘤医院病理专家的结果为准。同时通过问卷调查收集筛查对象及乡医村医有关HPV及筛查项目的认知和态度。最终有894名女性完成careHPV DNA检测,552名女性完成醋酸碘染肉眼观察,547名女性完成巴氏涂片。careHPV检测、醋酸碘染肉眼观察和巴氏涂片的阳性率分别为10.6%,18.1%和4.9%,差异具有统计学意义(χ~2=48.647,P<0.001)。总人群的CIN2+病变检出率为0.5%,尽管careHPV组的CIN2+病变检出率高于其他两组,但差异未发现统计学意义。通过以上研究,显示基层卫生工作人员对HPV相关知识的了解不足,但对于在国家筛查项目中引入HPV检测持积极的态度。在基层条件下由经过简单培训的实验员进行careHPV检测是可行的,应在基层卫生工作者中开展HPV及其检测相关的教育和培训。

细胞学及阴道镜检查对宫颈病变的诊断价值

目的评价细胞学及阴道镜检查对宫颈病变的诊断价值。方法以宫颈环型电切术(LEEP)后病理诊断为标准,对照分析巴氏涂片、液基薄层细胞检测(TCT)、阴道镜、细胞学联合阴道镜检查对400例患者宫颈病变的筛查结果。结果巴氏涂片灵敏度64.9%,特异度85.4%,假阴性率35.1%,假阳性率14.6%;TCT灵敏度77.8%,特异度80.7%,假阴性率22.2%,假阳性率19.3%;阴道镜灵敏度92.5%,特异度74.3%,假阴性率7.5%,假阳性率25.7%;阴道镜诊断不足19例(8.2%),诊断过度54例(23.2%);细胞学联合阴道镜灵敏度92.9%,特异度64.1%,假阴性率7.1%,假阳性率35.9%。巴氏涂片与TCT的检出率比较,差异无统计学意义(P>0.05);阴道镜和细胞学联合阴道镜检查的检出率明显高于细胞学检查(P<0.05)。结论细胞学联合阴道镜检查是较为理想的宫颈病变筛查方法,阴道镜诊断宫颈病变仍存在一定的漏诊率,尚无法代替LEEP。

以宫颈活检为基础评价液基细胞学检查在宫颈癌筛查中的价值

目的:液基细胞学能提高异常细胞的检出率和降低不满意涂片率,因此比传统巴氏涂片更敏感,但还存在争议,我们以病理活检为基础,对AutoCytePREP液基细胞学检查(LCT)在宫颈癌筛查中的价值进行评价。方法:采用横断面研究方法,所有病例来源于我院2004年11月～2006年9月妇科门诊,其中316例病人有完整资料包括细胞学检查(LCT组181例,巴氏涂片组135例)及阴道镜下活检结果,细胞学(LCT或巴氏涂片)采用TBS细胞分类法做出诊断,以≥LSIL为阳性,宫颈活检病理结果为"金标准",以≥CIN2为阳性。结果:LCT的敏感性为0.906,特异性为0.828,巴氏涂片的敏感性为0.710,特异性为0.836。结论:与传统巴氏涂片相比,LCT有较高的敏感性(P<0.05),而两者特异性无明显差别。